Back to Search
RAKESH SALGIA, M.D.
Pulmonary Disease Physician
NPI: 1972609022IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
036-068002(IL)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
036-068002(IL)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
036-068002(IL)
Education
OTHER
Class of 1980
Research & Publications (20)
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
PMID 19651775·J Biol Chem·2009
7-preclinical
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
PMID 19015641·Oncogene·2009
7-preclinical
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
PMID 19318576·Cancer Res·2009
7-preclinical
Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases.
PMID 19210585·J Cutan Pathol·2009
5-case
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
PMID 19139719·Lab Invest·2009
8-other
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.
PMID 19392863·Aliment Pharmacol Ther·2009
1-meta
Expression and mutational analysis of MET in human solid cancers.
PMID 18709663·Genes Chromosomes Cancer·2008
8-other
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
PMID 18340114·Cancer Biol Ther·2008
7-preclinical
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
PMID 18172305·Cancer Res·2008
7-preclinical
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
PMID 18281659·J Clin Oncol·2008
3-trial
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
PMID 18543326·Cancer·2008
3-trial
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
PMID 18423560·Gynecol Oncol·2008
3-trial
Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.
PMID 19061284·Arch Pathol Lab Med·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 67 W 111TH ST, SUITE 301
CHICAGO, IL 60628 - Phone
- (773) 995-3401
Quick Facts
- NPI
- 1972609022
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile